PE20060715A1 - Proceso de produccion de anti - abeta - Google Patents
Proceso de produccion de anti - abetaInfo
- Publication number
- PE20060715A1 PE20060715A1 PE2005000986A PE2005000986A PE20060715A1 PE 20060715 A1 PE20060715 A1 PE 20060715A1 PE 2005000986 A PE2005000986 A PE 2005000986A PE 2005000986 A PE2005000986 A PE 2005000986A PE 20060715 A1 PE20060715 A1 PE 20060715A1
- Authority
- PE
- Peru
- Prior art keywords
- cumulative
- crop
- group
- conditions
- period
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title 1
- 230000001186 cumulative effect Effects 0.000 abstract 5
- 230000001413 cellular effect Effects 0.000 abstract 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 abstract 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 abstract 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 abstract 2
- 229940024606 amino acid Drugs 0.000 abstract 2
- 235000001014 amino acid Nutrition 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 229960001230 asparagine Drugs 0.000 abstract 2
- 235000009582 asparagine Nutrition 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 230000003698 anagen phase Effects 0.000 abstract 1
- 229910001410 inorganic ion Inorganic materials 0.000 abstract 1
- 238000011031 large-scale manufacturing process Methods 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/04—Plant cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/04—Immortalised cells
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
REFERIDA A UN METODO PARA PRODUCIR ANTI - ABETA EN UN CULTIVO CELULAR DE PRODUCCION A GRAN ESCALA, EL CUAL COMPRENDE LAS ETAPAS DE: PROPORCIONAR UN CULTIVO CELULAR QUE COMPRENDE CELULAS DE MAMIFERO QUE CONTIENEN UN GEN QUE CODIFICA ANTI - ABETA, CUYO GEN SE EXPRESA BAJO UNA CONDICION DE CULTIVO CELULAR; Y UN MEDIO QUE CONTIENE GLUTAMINA Y QUE TIENE UNA CARACTERISTICA DE MEDIO SELECCIONADA DE: (I) UNA CANTIDAD DE AMINOACIDO ACUMULATIVO POR VOLUMEN UNITARIO MAYOR DE 80 mM, (ii) UNA RELACION MOLAR DE GLUTAMINA ACUMULATIVA A ASPARAGINA ACUMULATIVA DE MENOS DE 2, (iii) UNA RELACION MOLAR DE ION INORGANICO ACUMULATIVO A AMINOACIDO TOTAL ACUMULATIVO ENTRE 0,4 A 1, (v) UNA CANTIDAD ACUMULATIVA COMBINADA DE GLUTAMINA Y ASPARAGINA POR VOLUMEN UNITARIO DE MAS DE 16 mM, Y COMBINACIONES DE LOS MISMOS;MANTENER DICHO CULTIVO EN UNA FASE DE CRECIMIENTO INICIAL BAJO UN PRIMER GRUPO DE CONDICIONES DE CULTIVO DURANTE UN PRIMER PERIODO DE TIEMPO SUFICIENTE PARA PERMITIR QUE DICHAS CELULAS SE REPRODUZCAN EN UNA DENSIDAD CELULAR VIABLE DENTRO DE UN LIMITE DE 20%-80% DE LA DENSIDAD CELULAR VIABLE MAXIMA POSIBLE SI DICHO CULTIVO FUERA MANTENIDO BAJO UN PRIMER GRUPO DE CONDICIONES DE CULTIVO; CAMBIAR POR LO MENOS UNA DE LAS CONDICIONES DE CULTIVO, DE MODO QUE SE APLIQUE UN SEGUNDO GRUPO DE CONDICIONES DE CULTIVO; MANTENER DICHO CULTIVO DURANTE UN SEGUNDO PERIODO DE TIEMPO BAJO EL SEGUNDO GRUPO DE CONDICIONES Y DURANTE UN SEGUNDO PERIODO DE TIEMPO DE MODO QUE SE ACUMULE EL ANTI-ABETA EN EL CULTIVO
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60493604P | 2004-08-27 | 2004-08-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20060715A1 true PE20060715A1 (es) | 2006-08-15 |
Family
ID=35500647
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2009001268A PE20100147A1 (es) | 2004-08-27 | 2005-08-26 | PRODUCCION DE a-BETA |
| PE2005000986A PE20060715A1 (es) | 2004-08-27 | 2005-08-26 | Proceso de produccion de anti - abeta |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2009001268A PE20100147A1 (es) | 2004-08-27 | 2005-08-26 | PRODUCCION DE a-BETA |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US7335491B2 (es) |
| EP (2) | EP1781803B1 (es) |
| JP (3) | JP2008511328A (es) |
| KR (1) | KR100998857B1 (es) |
| CN (1) | CN101048512B (es) |
| AR (1) | AR050471A1 (es) |
| AU (1) | AU2005280090A1 (es) |
| BR (1) | BRPI0514680A (es) |
| CA (1) | CA2578137C (es) |
| CR (1) | CR8996A (es) |
| EC (1) | ECSP077351A (es) |
| EG (1) | EG25848A (es) |
| ES (1) | ES2599103T3 (es) |
| HN (1) | HN2005000486A (es) |
| IL (1) | IL181587A (es) |
| MX (1) | MX2007002382A (es) |
| MY (1) | MY146097A (es) |
| NO (1) | NO20071571L (es) |
| NZ (1) | NZ591233A (es) |
| PE (2) | PE20100147A1 (es) |
| RU (1) | RU2418858C2 (es) |
| SG (1) | SG155250A1 (es) |
| SV (1) | SV2006002212A (es) |
| TW (1) | TWI374935B (es) |
| UA (1) | UA89644C2 (es) |
| WO (1) | WO2006026408A2 (es) |
| ZA (1) | ZA200702487B (es) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| US7300773B2 (en) | 2004-08-27 | 2007-11-27 | Wyeth Research Ireland Limited | Production of TNFR-Ig |
| US7335491B2 (en) | 2004-08-27 | 2008-02-26 | Wyeth Research Ireland Limited | Production of anti-abeta |
| TWI384069B (zh) | 2004-08-27 | 2013-02-01 | Pfizer Ireland Pharmaceuticals | 多胜肽之製法 |
| PE20070796A1 (es) * | 2005-10-24 | 2007-08-15 | Wyeth Corp | Metodo de produccion proteica utilizando compuestos anti-senescencia |
| US20070231895A1 (en) * | 2005-11-02 | 2007-10-04 | Lee Gene W | Methods for adapting mammalian cells |
| PL1976877T5 (pl) | 2005-11-30 | 2017-09-29 | Abbvie Inc | Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania |
| CN117903302A (zh) | 2005-11-30 | 2024-04-19 | Abbvie 公司 | 抗-Aβ球聚体抗体，其相关产品，生产所述抗体的方法，所述抗体的应用以及使用方法 |
| RU2551782C2 (ru) | 2005-12-12 | 2015-05-27 | Ац Иммуне Са | Специфические в отношении амилоида бета (а бета) 1-42 моноклональные антитела, обладающие терапевтическими свойствами |
| CA2657248C (en) | 2006-07-13 | 2018-10-30 | Wyeth | Production of glycoproteins |
| WO2008011348A2 (en) * | 2006-07-14 | 2008-01-24 | Ac Immune S.A. | Humanized antibody against amyloid beta |
| CA2666317C (en) * | 2006-11-03 | 2013-08-06 | Wyeth | Glycolysis-inhibiting substances in cell culture |
| PL2078071T3 (pl) * | 2006-11-08 | 2015-07-31 | Wyeth Llc | Racjonalnie opracowane pożywki do hodowli komórek |
| US8455626B2 (en) * | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| EP2486928A1 (en) * | 2007-02-27 | 2012-08-15 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
| MX2009009234A (es) | 2007-03-01 | 2009-12-01 | Probiodrug Ag | Uso nuevo de inhibidores de ciclasa de glutaminilo. |
| DK2115126T3 (en) * | 2007-03-02 | 2015-05-04 | Wyeth Llc | Use of copper and glutamate in cell culture for the preparation of polypeptides |
| EP2865670B1 (en) | 2007-04-18 | 2017-01-11 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
| TW200902708A (en) * | 2007-04-23 | 2009-01-16 | Wyeth Corp | Methods of protein production using anti-senescence compounds |
| CN101663391A (zh) | 2007-04-26 | 2010-03-03 | 中外制药株式会社 | 使用含高浓度氨基酸的培养基的细胞培养方法 |
| US8613923B2 (en) * | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| TW201518320A (zh) * | 2007-06-12 | 2015-05-16 | Ac Immune Sa | 特異性結合β-類澱粉蛋白之抗體及相關核酸分子、表現載體、細胞、組合物、套組、方法及用途 |
| US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| EP2586795B1 (en) * | 2007-10-05 | 2018-05-16 | Genentech, Inc. | Use of anti-amyloid beta antibody in ocular diseases |
| PL2310523T3 (pl) * | 2008-04-17 | 2015-10-30 | Wyeth Llc | Sposoby zwiększonego wytwarzania białek morfogenetycznych kości |
| WO2010031074A2 (en) | 2008-09-15 | 2010-03-18 | Genentech, Inc. | Compositions and methods for regulating cell osmolarity |
| PT2464725T (pt) | 2009-08-11 | 2020-05-21 | Hoffmann La Roche | Produção de proteínas em meios de cultura celular isentos de glutamina |
| ES2548913T3 (es) | 2009-09-11 | 2015-10-21 | Probiodrug Ag | Derivados heterocíclicos como inhibidores de glutaminil ciclasa |
| US8470552B2 (en) * | 2009-10-12 | 2013-06-25 | Keck Graduate Institute | Strategy to reduce lactic acid production and control PH in animal cell culture |
| ES2586231T3 (es) | 2010-03-03 | 2016-10-13 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
| AU2011226074B2 (en) | 2010-03-10 | 2015-01-22 | Vivoryon Therapeutics N.V. | Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5) |
| CA2796339C (en) | 2010-04-15 | 2020-03-31 | Abbott Laboratories | Amyloid-beta binding proteins |
| EP2560953B1 (en) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
| EP2563906B1 (en) | 2010-04-26 | 2017-11-08 | Novartis AG | Process for cultivation of cho cells |
| KR101828623B1 (ko) | 2010-04-26 | 2018-02-12 | 노파르티스 아게 | 개선된 세포 배양 배지 |
| WO2011134921A1 (en) | 2010-04-26 | 2011-11-03 | Novartis Ag | Improved cell culture medium |
| CN103179981B (zh) | 2010-07-30 | 2017-02-08 | Ac免疫有限公司 | 安全和功能性的人源化抗β‑淀粉样蛋白抗体 |
| CA2808187A1 (en) | 2010-08-14 | 2012-02-23 | Abbvie Inc. | Amyloid-beta binding proteins |
| CA2807607A1 (en) | 2010-08-20 | 2012-02-23 | Wyeth Llc | Cell culture of growth factor-free adapted cells |
| US8530670B2 (en) | 2011-03-16 | 2013-09-10 | Probiodrug Ag | Inhibitors |
| FI20115704L (fi) | 2011-07-01 | 2013-01-02 | Teknologian Tutkimuskeskus Vtt Oy | Vierasproteiinien tuoton parantaminen |
| LT2837680T (lt) * | 2011-07-01 | 2020-07-10 | Amgen Inc. | Žinduolių ląstelių kultūra |
| US9217168B2 (en) | 2013-03-14 | 2015-12-22 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
| SG11201601681QA (en) | 2013-10-11 | 2016-04-28 | Regeneron Pharma | Metabolically optimized cell culture |
| US11390663B2 (en) | 2013-10-11 | 2022-07-19 | Regeneron Pharmaceuticals, Inc. | Metabolically optimized cell culture |
| DE102017203908B3 (de) * | 2017-03-09 | 2018-05-30 | Evonik Technochemie Gmbh | Kulturmedium, umfassend Oligopeptide |
| WO2018229274A1 (en) * | 2017-06-16 | 2018-12-20 | Katholieke Universiteit Leuven | Cell culture media for differentiation of stem cells into hepatocytes |
| DK3461819T3 (da) | 2017-09-29 | 2020-08-10 | Probiodrug Ag | Inhibitorer af glutaminylcyklase |
| BR112020025623A2 (pt) * | 2018-07-03 | 2021-03-23 | Bristol-Myers Squibb Company | métodos de produção de proteínas recombinantes |
| BR112021025438A2 (pt) | 2019-12-06 | 2022-06-21 | Regeneron Pharma | Composições de proteínas anti-vegf e métodos para produzir as mesmas |
| AU2021223568A1 (en) | 2020-02-18 | 2022-07-14 | Boehringer Ingelheim International Gmbh | Mammalian cell culture processes |
| TW202216760A (zh) | 2020-07-23 | 2022-05-01 | 愛爾蘭商歐薩爾普羅席納有限公司 | 抗類澱粉β (ABETA)抗體 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) * | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4522811A (en) * | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
| GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5672502A (en) * | 1985-06-28 | 1997-09-30 | Celltech Therapeutics Limited | Animal cell culture |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US6048728A (en) * | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
| EP0435911B1 (en) * | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| US6291159B1 (en) * | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for producing polymers having a preselected activity |
| US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
| NZ235148A (en) * | 1989-09-05 | 1991-12-23 | Immunex Corp | Tumour necrosis factor receptor protein and dna sequences |
| US5395760A (en) | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
| JPH0396383A (ja) | 1989-09-08 | 1991-04-22 | Riso Kagaku Corp | 画像形成装置 |
| DK0417563T3 (da) | 1989-09-12 | 2000-11-06 | Hoffmann La Roche | TNF-bindende proteiner |
| DK0494955T3 (da) | 1989-10-05 | 1998-10-26 | Optein Inc | Cellefri syntese og isolering af hidtil ukendte gener og polypeptider |
| US6657103B1 (en) * | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5538983A (en) * | 1990-05-16 | 1996-07-23 | The Rockefeller University | Method of treating amyloidosis by modulation of calcium |
| US5156964A (en) * | 1990-08-16 | 1992-10-20 | Cetus Corporation | Methods for adapting cells for increased product production through exposure to ammonia |
| US5122469A (en) * | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| GB9021679D0 (en) | 1990-10-05 | 1990-11-21 | Gorman Scott David | Antibody preparation |
| GB9022545D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Culture medium |
| GB2251249B (en) | 1990-12-28 | 1995-06-21 | Mogam Biotech Res Inst | High-density medium for animal cell culture |
| JPH059735A (ja) * | 1991-07-09 | 1993-01-19 | Kobe Steel Ltd | ダイヤモンドの気相合成方法 |
| GB9118664D0 (en) * | 1991-08-30 | 1991-10-16 | Celltech Ltd | Cell culture |
| US5447851B1 (en) * | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
| JP3504963B2 (ja) | 1993-10-22 | 2004-03-08 | 智靖 羅 | 抗ヒト高親和性ＩｇＥ受容体モノクローナル抗体に係るアミノ酸配列をコードするＤＮＡ断片 |
| US6310185B1 (en) * | 1994-03-08 | 2001-10-30 | Memorial Sloan Kettering Cancer Center | Recombinant human anti-Lewis Y antibodies |
| US5856179A (en) * | 1994-03-10 | 1999-01-05 | Genentech, Inc. | Polypeptide production in animal cell culture |
| US5589154A (en) * | 1994-11-22 | 1996-12-31 | Rutgers, The State University Of New Jersey | Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease |
| US5705364A (en) * | 1995-06-06 | 1998-01-06 | Genentech, Inc. | Mammalian cell culture process |
| US5721121A (en) * | 1995-06-06 | 1998-02-24 | Genentech, Inc. | Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein |
| JP4306813B2 (ja) * | 1995-09-19 | 2009-08-05 | アスビオファーマ株式会社 | 動物細胞の新規培養方法 |
| CN1233189A (zh) * | 1996-05-08 | 1999-10-27 | 弗·哈夫曼-拉罗切有限公司 | 用TNFR-Ig治疗哮喘 |
| WO1998041611A1 (en) * | 1997-03-20 | 1998-09-24 | Regents Of The University Of Minnesota | Process for the continuous culture of cells |
| US20020012991A1 (en) | 1997-04-07 | 2002-01-31 | Florence Chua Nee Ho Kit Fong | Cell culture media for enhanced protein production |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| CA2354862A1 (en) | 1998-10-19 | 2000-04-27 | Yeda Research And Development Co. Ltd. | Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens |
| PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
| TW200526779A (en) | 2001-02-08 | 2005-08-16 | Wyeth Corp | Modified and stabilized GDF propeptides and uses thereof |
| ES2312569T3 (es) | 2001-04-30 | 2009-03-01 | Eli Lilly And Company | Anticuerpos humanizados. |
| ES2437875T3 (es) | 2001-04-30 | 2014-01-14 | Eli Lilly And Company | Anticuerpos humanizados que reconocen el péptido beta-amiloide |
| US20030087372A1 (en) | 2001-06-13 | 2003-05-08 | Genentech, Inc. | Methods of culturing animal cells and polypeptide production in animal cells |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| MXPA04008150A (es) | 2002-02-21 | 2005-06-17 | Wyeth Corp | Gasp1: una proteina que contiene dominio de folistatina. |
| KR20040096592A (ko) | 2002-02-21 | 2004-11-16 | 와이어쓰 | 폴리스타틴 도메인을 포함하는 단백질 |
| MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| PL224001B1 (pl) | 2002-05-02 | 2016-11-30 | Wyeth Corp | Sposób wytwarzania stabilnej liofilizowanej kompozycji obejmującej monomeryczne koniugaty pochodna kalicheamycyny/przeciwciało anty-CD22, kompozycja otrzymana tym sposobem oraz jej zastosowanie |
| US7261893B2 (en) | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
| US20040223966A1 (en) | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| US7300773B2 (en) | 2004-08-27 | 2007-11-27 | Wyeth Research Ireland Limited | Production of TNFR-Ig |
| TWI384069B (zh) | 2004-08-27 | 2013-02-01 | Pfizer Ireland Pharmaceuticals | 多胜肽之製法 |
| US7335491B2 (en) | 2004-08-27 | 2008-02-26 | Wyeth Research Ireland Limited | Production of anti-abeta |
-
2005
- 2005-08-25 US US11/213,317 patent/US7335491B2/en not_active Expired - Fee Related
- 2005-08-25 TW TW094129074A patent/TWI374935B/zh not_active IP Right Cessation
- 2005-08-26 JP JP2007530148A patent/JP2008511328A/ja active Pending
- 2005-08-26 MY MYPI20054022A patent/MY146097A/en unknown
- 2005-08-26 AU AU2005280090A patent/AU2005280090A1/en not_active Abandoned
- 2005-08-26 UA UAA200703284A patent/UA89644C2/ru unknown
- 2005-08-26 RU RU2007108718/10A patent/RU2418858C2/ru not_active IP Right Cessation
- 2005-08-26 SG SG200905720-9A patent/SG155250A1/en unknown
- 2005-08-26 PE PE2009001268A patent/PE20100147A1/es not_active Application Discontinuation
- 2005-08-26 WO PCT/US2005/030364 patent/WO2006026408A2/en active Application Filing
- 2005-08-26 MX MX2007002382A patent/MX2007002382A/es active IP Right Grant
- 2005-08-26 KR KR1020077004809A patent/KR100998857B1/ko not_active IP Right Cessation
- 2005-08-26 CN CN2005800368972A patent/CN101048512B/zh not_active Expired - Fee Related
- 2005-08-26 BR BRPI0514680-1A patent/BRPI0514680A/pt not_active Application Discontinuation
- 2005-08-26 NZ NZ591233A patent/NZ591233A/xx not_active IP Right Cessation
- 2005-08-26 EP EP05791655.3A patent/EP1781803B1/en active Active
- 2005-08-26 PE PE2005000986A patent/PE20060715A1/es not_active Application Discontinuation
- 2005-08-26 CA CA2578137A patent/CA2578137C/en not_active Expired - Fee Related
- 2005-08-26 ES ES05791655.3T patent/ES2599103T3/es active Active
- 2005-08-26 AR ARP050103595A patent/AR050471A1/es not_active Application Discontinuation
- 2005-08-26 EP EP10184494A patent/EP2348126A3/en not_active Withdrawn
- 2005-08-26 HN HN2005000486A patent/HN2005000486A/es unknown
- 2005-08-26 SV SV2005002212A patent/SV2006002212A/es unknown
-
2007
- 2007-02-27 EG EGNA2007000224 patent/EG25848A/xx active
- 2007-02-27 IL IL181587A patent/IL181587A/en not_active IP Right Cessation
- 2007-03-16 CR CR8996A patent/CR8996A/es unknown
- 2007-03-26 ZA ZA2007/02487A patent/ZA200702487B/en unknown
- 2007-03-26 NO NO20071571A patent/NO20071571L/no not_active Application Discontinuation
- 2007-03-27 EC EC2007007351A patent/ECSP077351A/es unknown
-
2012
- 2012-02-17 JP JP2012033105A patent/JP2012095671A/ja active Pending
-
2015
- 2015-04-01 JP JP2015075425A patent/JP2015133980A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20060715A1 (es) | Proceso de produccion de anti - abeta | |
| AR050537A1 (es) | Produccion de proteina de fusion tnfr-ig | |
| ES2628012T3 (es) | Producción de TNFR-Ig en un cultivo celular de producción a gran escala | |
| AR111785A2 (es) | Método in vitro de producción de eritrocitos | |
| NI200800111A (es) | Método de producción proteica utilizando compuestos anti-senescencia | |
| ATE491156T1 (de) | Bio-elektrochemisches verfahren zur herstellung von wasserstoff | |
| AR113772A1 (es) | Biorreactor de perfusión y métodos de uso relacionados | |
| WO2004044142A3 (en) | Mesenchymal stem cells and methods of use thereof | |
| BRPI0514778A (pt) | meio e cultivo das células tronco embriÈnica | |
| MX2021005021A (es) | Proceso para producir celulas t geneticamente modificadas. | |
| CU20120006A7 (es) | Producción de títulos elevados de poliovirus para la producción de vacunas | |
| AR069956A1 (es) | Procesos para cultivar celulas mamiferas secretoras de proteinas sanguineas heterologas | |
| DK1851815T3 (da) | Fremgangsmåde til fremstilling af en brændselscellekatode | |
| CY1107919T1 (el) | Αντιδραστηρας εκθεσης σε φαση υγρου/αεριου για την καλλιεργεια κυτταρων | |
| WO2009016078A3 (en) | Method for culturing mammalian stem cells | |
| BRPI0518449A2 (pt) | mÉtodos para produzir cÉlulas mamÍferas | |
| CN105702993B (zh) | 双室微滤膜多阳极型微藻生物燃料电池 | |
| WO2006127619A3 (en) | Cell culture | |
| CN108811894A (zh) | 一种用植物光合作用进行发电的花盆 | |
| UA67135A (en) | Method for producing lithium battery | |
| DK1287118T3 (da) | Fremgangsmåde til fremstilling af et recipientspecifikt vævstransplantat eller -implantat | |
| Narula | Generation of electricity using Spartina Patens with stainless steel current collectors in a plant-microbial fuel cell | |
| CO2023018654A2 (es) | Método para producir linfocitos citolíticos naturales a partir de células madre pluripotentes | |
| EP0987324A3 (en) | Cell growth accelerator containing polyphosphoric acid and cell growth method using the same | |
| CN110093261A (zh) | 一种用于沉积物中厌氧菌原位分离的装置及使用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |